EGFR and colorectal carcinoma: Another phase II prospective study by Fora et al. reported benefit from EGFR retreatment with a higher dose of cetuximab (500 mg/m2 weekly) in combination with irinotecan in 20 KRAS-wt metastatic CRC patients who had previously progressed on both agents [9].